Insmed Statistics
Insmed (IM8N) Stock Statistics & Valuation Metrics
Total Valuation
Insmed has a market cap or net worth of EUR 23.47B. The enterprise value is EUR 24.58B.
- Market Cap
- EUR 23.47B
- Enterprise Value
- EUR 24.58B
Share Statistics
Insmed has 219,380,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 219,380,310
- Owned by Insiders
- 0.70%
- Owned by Institutions
- 53.27%
Financial Efficiency
Insmed’s return on equity (ROE) is -1.73 and return on invested capital (ROIC) is -64.84%.
- Return on Equity (ROE)
- -1.73
- Return on Assets (ROA)
- -0.56
- Return on Invested Capital (ROIC)
- -64.84%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 364.44K
- Profits Per Employee
- -767.29K
- Employee Count
- 1,664
- Asset Turnover
- 0.27
- Inventory Turnover
- 0.95
Valuation Ratios
The current PE Ratio of Insmed is -42.37. Insmed’s PEG ratio is -0.53.
- PE Ratio
- -42.37
- PS Ratio
- 17.25
- PB Ratio
- 36.00
- Price to FCF
- -39.86
- Price to Operating Cash Flow
- -43.89
- PEG Ratio
- -0.53
Income Statement
In the last 12 months, Insmed had revenue of 606.42M and earned -1.28B in profits. Earnings per share was -6.41.
- Revenue
- 606.42M
- Gross Profit
- 481.55M
- Operating Income
- -1.18B
- Pretax Income
- -1.27B
- Net Income
- -1.28B
- EBITDA
- -1.17B
- Earnings Per Share (EPS)
- -6.41
Cash Flow
In the last 12 months, operating cash flow was -595.62M and capital expenditures -61.95M, giving a free cash flow of -657.58M billion.
- Operating Cash Flow
- -595.62M
- Free Cash Flow
- -657.58M
- Free Cash Flow per Share
- -3.01
Dividends & Yields
Insmed pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.55%
- Earnings Yield
- -2.35%
Stock Price Statistics
- Beta
- 0.16
- 52-Week Price Change
- -37.38%
- 50-Day Moving Average
- 97.97
- 200-Day Moving Average
- 106.52
- Relative Strength Index (RSI)
- 66.03
- Average Volume (3m)
- 81
Important Dates
Insmed upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Insmed as a current ratio of 3.83, with Debt / Equity ratio of 103.95%
- Current Ratio
- 3.83
- Quick Ratio
- 3.54
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.22
- Interest Coverage Ratio
- -14.04
Taxes
In the past 12 months, Insmed has paid 5.03M in taxes.
- Income Tax
- 5.03M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Insmed EV to EBITDA ratio is -52.97, with an EV/FCF ratio of -39.79.
- EV to Sales
- 17.21
- EV to EBITDA
- -52.97
- EV to Free Cash Flow
- -39.79
- EV to Operating Cash Flow
- -43.92
Balance Sheet
Insmed has EUR 1.15B in cash and marketable securities with EUR 741.17M in debt, giving a net cash position of EUR 405.46M billion.
- Cash & Marketable Securities
- EUR 1.15B
- Total Debt
- EUR 741.17M
- Net Cash
- EUR 405.46M
- Net Cash Per Share
- EUR 1.85
- Tangible Book Value Per Share
- EUR 2.06
Margins
Gross margin is 84.26%, with operating margin of -35.59%, and net profit margin of -39.85%.
- Gross Margin
- 84.26%
- Operating Margin
- -35.59%
- Pretax Margin
- -39.35%
- Net Profit Margin
- -39.85%
- EBITDA Margin
- -32.50%
- EBIT Margin
- -34.09%
Analyst Forecast
The average price target for Insmed is EUR 169.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 169.27
- Price Target Upside
- 60.90% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- 225.31%
- EPS Growth Forecast
- 56.58%
Scores
- Smart Score
- 6
- AI Score
- ―
